Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Study Details
Study Description
Brief Summary
The purpose of this study is to determine whether the combination with ramipril and clopidogrel leads to further improvement of endothelial function, reduction of oxidative stress and reduction of vascular inflammation, compared with ramipril monotherapy, in patients with Diabetes Mellitus type 2 and diabetic nephropathy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
-
Cardiovascular disease is the leading cause of deaths in diabetic population with diabetic nephropathy.
-
Pharmacologic therapy for patients with diabetes and hypertension should be with a regimen that includes either an angiotensin-converting-enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB)
-
Diabetic patients at increased cardiovascular risk should receive an antiplatelet agent for primary prevention.
Methods:
An open label,randomized, two period cross-over design study, involving patients with type 2 diabetes and diabetic nephropathy. After a 4 weeks wash out period for ACE inhibitors or Angiotensin receptor blockers (week 0, baseline) 60 patients will be randomized to receive ramipril(10 mg) only or ramipril (10 mg) and clopidogrel (75mg) for 12 weeks exchanging their treatment for a further 12 weeks, after a 2 week wash out period for clopidogrel. Patients will be examined and measurements will be taken at baseline (week 0), and at the end of 12, 14, and 26 weeks.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: ramipril Ramipril 10 mg tablets. Each dose will be taken orally with water once daily. |
Drug: Ramipril
Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
Other Names:
|
| Active Comparator: clopidogrel and ramipril clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily |
Drug: Ramipril
Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
Other Names:
Drug: Clopidogrel
12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy [Baseline to week 12 and week 14 to week 26]
The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in ADMA as biomarker of endothelial dysfunction.
- Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy [Baseline to week 12 and week 14 to week 26]
The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in hsCRP as biomarker of vascular inflammation
- Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy [Baseline to week 12 and week 14 to week 26]
The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in soluble CD40 Ligand as biomarker of vascular inflammation.
- Changes in urine 8-isoprostane-F2 levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy [Baseline to week 12 and week 14 to week 26]
The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in urine 8-isoprostane-F2 as biomarker of oxidative stress.
- Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy [Baseline to week 12 and week 14 to week 26]
The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in albumine to creatine ratio as an index of cardiovascular disease
Secondary Outcome Measures
- Changes in ADMA blood levels after treatment with ramipril [baseline to week 26]
Evaluation of the effect of ramipril, as antihypertensive therapy, in endothelial dysfunction in patients with diabetes mellitus type 2 and diabetic nephropathy
- Increase of Glomerular Filtration Rate (GFR) after combined treatment with ramipril and clopidogrel and after ramipril monotherapy [baseline to week 12 and week 14 to week 26]
- Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy [baselibe to week 12 and week 14 to week 26]
Eligibility Criteria
Criteria
Inclusion Criteria: type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria and
-
HbA1c(glycosylated haemoglobin A1c <7%
-
Blood pressure ≤130/80 mmHg
-
LDL (Low Density Lipoproteins) <100 mg/dl
-
Informed consent
Exclusion Criteria:
-
patients with diabetic nephropathy and estimated GFR <30ml/min with Modification of Diet in Renal Disease equation (MDRD equation)
-
baseline potassium > 5.2 meq/L
-
patients with nephrotic proteinuria defined as albumine to creatinine ratio (ACR)> 3.5 g/g or as proteinuria >3.5 g per 1.73 m2 per 24 hours
-
history or evidence of non-diabetic kidney disease
-
history of stroke, peripheral artery disease, coronary artery disease
-
history or evidence of a secondary form of hypertension
-
history of severe hepatic failure, malignancy, severe endocrinopathy,autoimmune disease or chronic inflammatory disease
-
any known bleeding or platelet disorder or platelets <100.000/μL
-
heart failure in New York Heart Association(NYHA) functional class II-IV
-
inability or unwillingness on the part of the patient to sign the Patient Consent Form
-
known hypersensitivity to ramipril or to clopidogrel
-
Women of child-bearing potential
-
use of oral anticoagulants or other antithrombotic treatment
-
use of glitazones
-
patients receiving statins should be on a stable dose of at least 3 months prior to study initiation and dose should be constant during the study
-
any surgical or medical condition which in the opinion of the investigator may expose the patient to a higher risk in participation in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | AHEPA University Hospital | Thessaloniki | Greece | 546 36 | |
| 2 | Aristotle University of Thessaloniki/ AHEPA University Hospital | Thessaloniki | Greece |
Sponsors and Collaborators
- AHEPA University Hospital
- Aristotle University Of Thessaloniki
Investigators
- Study Director: Fotios S Iliadis, Lecturer of Internal Medicine, AHEPA University Hospital/ Aristotle University of Thessaloniki
- Principal Investigator: Vaia F Bougatsa, Resident of Internal Medicine, AHEPA University Hospital/ Aristotle University of Thessaloniki
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 15/10-7-2012